Add BrightSurf on Google Email

TGen-UCSF study uses genomics to make treatment calls for recurrent glioblastoma patients

Researchers have developed a comprehensive genomic sequencing approach that guides timely treatment for recurring brain cancer, resulting in extended progression-free survival. Two patients survived over a year without disease recurrence, demonstrating the potential of precision medicine in aggressive and refractory tumors.

SourceThe Translational Genomics Research Institute·JournalClinical Cancer Research·DateOct 27, 2017

DNA mutations shed in blood predicts response to immunotherapy in patients with cancer

A study by University of California San Diego School of Medicine researchers reveals that a simple blood test can predict which patients will respond to checkpoint inhibitor-based immunotherapies, with 45% of patients showing significant response. The findings suggest that patients with high numbers of genomic alterations in their tumo...

SourceUniversity of California - San Diego·JournalClinical Cancer Research·DateOct 2, 2017

Cancer hijacks natural cell process to survive

Researchers at the University of Oxford have discovered that cancer cells manipulate a natural cell process called nonsense-mediated decay (NMD) to promote their survival. By understanding how NMD affects different types of cancer, scientists may be able to develop new treatments and therapies to control tumour growth.

SourceUniversity of Oxford·JournalNature Communications·DateJun 26, 2017

Endometrial cancer mutations are detectable in uterine lavage fluid before cancer diagnosis

Researchers discovered cancer-driving gene mutations in uterine lavage fluid of women with and without endometrial cancer. The study's findings suggest that these pre-cancerous mutations can be detected using advanced genomic technologies, potentially leading to earlier diagnosis and improved treatment outcomes.

Researchers uncover protein-based 'cancer signature'

A research team at the University of Basel has discovered a cancer type-specific 'signature' based on ribosomal protein expression. This signature may serve as a prognostic marker for cancer and point towards new therapeutic opportunities, with a strong relationship found between the signature in breast cancer and relapse-free survival.

SourceUniversity of Basel·JournalGenome Biology·DateDec 5, 2016

'Freeze-frame' proteins show how cancer evolves

Researchers capture elusive DNA reaction intermediates in living cells, discovering mechanisms underlying genome instability and a new role for an E. coli protein related to human cancer proteins. This breakthrough could lead to the development of new drugs that prevent cancer by neutralizing these key pieces of genetic code.

SourceRice University·JournalScience Advances·DateNov 18, 2016

Where does cisplatin bind?

Researchers develop universal assay to detect cisplatin cross-linking sites in the genome. They found that mitochondrial DNA is a major target of cisplatin's action, while nuclear DNA is less affected.

SourceWiley·JournalAngewandte Chemie International Edition·DateOct 21, 2016

New standard helps ensure accurate clinical measurements of HER2 breast cancer gene

A new measurement standard, developed by NIST, has been used to evaluate the performance of next-generation DNA-sequencing technologies for evaluating gene variations associated with an increased risk of breast cancer. The HER2 Standard Reference Material demonstrates its value in increasing confidence in reporting HER2 amplification f...

SourceNational Institute of Standards and Technology (NIST)·JournalJournal of Molecular Diagnostics·DateAug 17, 2016